At 23.7 months, half of the people receiving RYBREVANT® + LAZCLUZE™ lived without their cancer growing or spreading, compared with 16.6 months for osimertinib
These results are from a clinical trial where 858 people with advanced NSCLC with exon 19 deletion or exon 21 L858R received a first treatment of RYBREVANT® in combination with LAZCLUZE™ or a first treatment of osimertinib alone.
*Osimertinib is a preferred first treatment option for EGFR exon 19 deletion or exon 21 L858R mutations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non–Small Cell Lung Cancer V.7.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 19, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
RYBREVANT® + LAZCLUZE™
Tumors got smaller†: 73%
Tumors disappeared‡: 5%
Osimertinib
Tumors got smaller†: 70%
Tumors disappeared‡: 4%
Of people who responded, half were still responding at 25.8 months with RYBREVANT® + LAZCLUZE™ and 16.7 months with osimertinib.
Chemotherapy = carboplatin + pemetrexed
†Tumors getting smaller may also be called a partial response. This means the tumor got measurably smaller but is still detectable.
‡Tumors disappearing may also be called a complete response. This does not necessarily mean the cancer has been cured.
There are side effects that you may experience during treatment with RYBREVANT®.
Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.